Picture Demy-Colton BioFuture 2024 NYC Game Changers 650x100px
Collaboration › Details

Silence Therapeutics–Guggenheim: investor conference, 202402 supply service Silence Tx particpates in Guggenheim Healthcare Talks


Period Period 2024-02-07
Organisations Partner, 1st Silence Therapeutics plc (Nasdaq: SLN)
  Group Silence Therapeutics (Group)
  Partner, 2nd Guggenheim Securities, LLC
  Group Guggenheim (Group)
Products Product Guggenheim Healthcare Talks | Annual Biotechnology Conference 2024 New York
  Product 2 mRNAi GOLD™ platform
Person Person Hopkins, Gem (Silence Therapeutics 202202 Head of IR + Corporate Communications)

Silence Therapeutics plc. (1/31/24). "Press Release: Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference". London.

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7th at 1:30 p.m. ET.

The live webcast can be accessed via the Investors section of the Silence website at An archived replay of the webcast will be available following the conference.

About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include zerlasiran designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and divesiran designed to address rare hematological diseases, including polycythemia vera. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit



Silence Therapeutics plc
Gem Hopkins, Head of IR and Corporate Communications
Tel: +1 (646) 637-3208

Record changed: 2024-02-13


Picture [iito] [LSE] Business Portal 650x200px

More documents for Silence Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2024 NYC Reimagine Healthcare 650x300px

» top